# Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

> **NCT05061446** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 54 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Etrasimod
- **DRUG:** Etrasimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05061446
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-10
- **Primary completion:** 2023-10-06
- **Final completion:** 2023-10-06
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2024-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05061446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05061446, "Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05061446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*